Lack of correlation between the central anti-nociceptive and peripheral anti-inflammatory effects of selective COX-2 inhibitor parecoxib

Brain Research Bulletin

Volumn 80, Issue 1-2, 2009, Pages 56-61

  Urdaneta, A ^a   Siso, A ^a   Urdaneta, B ^a   Cardenas, R ^a   Quintero, L ^a   Avila, R ^a   Suarez Roca, H ^a  

^a UNIVERSIDAD DEL ZULIA   (Venezuela)

Author keywords

Cyclooxygenase inhibitors; Inflammation; Ketoprofen; Nociception; Parecoxib; Spinal cord

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; ISOENZYME; KETOPROFEN; PARECOXIB; PROTEIN C FOS;

ANALGESIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; CORRELATIONAL STUDY; DRUG EFFECT; DRUG MECHANISM; INFLAMMATION; LUMBAR SPINAL CORD; MALE; NERVE CELL; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SPINAL CORD DORSAL HORN;

ANALGESICS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARRAGEENAN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; EXTREMITIES; INFLAMMATION; ISOENZYMES; ISOXAZOLES; KETOPROFEN; MALE; MEMBRANE PROTEINS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 67650635150     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2009.05.009     Document Type: Article

References (38)

1. Abbadie C., and Besson J.M. Chronic treatments with aspirin or acetaminophen reduce both the development of polyarthritis and Fos-like immunoreactivity in rat lumbar spinal cord. Pain 57 (1994) 45-54
2. Aid S., Langenbach R., and Bosetti F. Neuroinflammatory response to lipopolysaccharide is exacerbated in mice genetically deficient in cyclooxygenase-2. J. Neuroinflammation 19 (2008) 17-31
3. Bannwarth B., Netter P., Pourel J., Royer R.J., and Gaucher A. Clinical pharmacokinetics of nonsteroidal anti-inflammatory drugs in the cerebrospinal fluid. Biomed. Pharmacother. 43 (1989) 121-126
4. Buritova J., Honoré P., and Besson J.M. Ketoprofen produces profound inhibition of spinal c-Fos protein expression resulting from an inflammatory stimulus but not from noxious heat. Pain 67 (1996) 379-389
5. Carrive P., and Meyer-Carrive I. Changes in formalin-evoked spinal Fos expression and nociceptive behaviour after oral administration of Bufferin A (aspirin) and L-5409709 (ibuprofen + caffeine + paracetamol). Pain 70 (1997) 253-266
6. Choi S.H., Langenbach R., and Bosetti F. Genetic deletion or pharmacological inhibition of cyclooxygenase-1 attenuate lipopolysaccharide-induced inflammatory response and brain injury. FASEB J. 22 (2008) 1491-1501
7. Coggeshall R.E. Fos, nociception and the dorsal horn. Prog. Neurobiol. 77 (2005) 299-352
8. Cryer B., and Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am. J. Med. 104 (1998) 413-421
9. Desjardins P.J., Grossman E.H., Kuss M.E., Talwalker S., Dhadda S., Baum D., and Hubbard R.C. The injectable cyclooxygenase-2-specific inhibitor parecoxib sodium has analgesic efficacy when administered preoperatively. Anesth. Analg. 93 (2001) 721-727
10. Giesler G.J.J., Menetrey D., and Basbaum A.I. Differential origins of spinothalamic tract projections to medial and lateral thalamus in the rat. J. Comp. Neurol. 184 (1979) 107-126
11. Honoré P., Buritova J., and Besson J.M. Aspirin and acetaminophen reduced both Fos expression in rat lumbar spinal cord and inflammatory signs produced by carrageenin inflammation. Pain 63 (1995) 365-375
12. Hunt S.P., Pini A., and Evan G. Induction of c-fos-like protein in spinal cord neurons following sensory stimulation. Nature 328 (1987) 632-634
13. Jain K.K. Evaluation of intravenous parecoxib for the relief of acute post-surgical pain. Expert Opin. Invest. Drugs 9 (2000) 2717-2723
14. Lee I.O., and Seo Y. The effects of intrathecal cyclooxygenase-1, cyclooxygenase-2, or nonselective inhibitors on pain behavior and spinal Fos-like immunoreactivity. Anesth. Analg. 106 (2008) 972-977
15. Liao S.L., Ou Y.C., Chen S.Y., Chiang A.N., and Chen C.J. Induction of cyclooxygenase-2 expression by manganese in cultured astrocytes. Neurochem. Int. 50 (2007) 905-915
16. Light A.R. The organization of nociceptive neurons in the spinal grey matter. In: Gildenberg P.L. (Ed). The Initial Processing of Pain and its Descending Control: Spinal and Trigeminal Systems (1992), Basel, Karger 109-177
17. Light A.R. Spinal terminations of nociceptive primary afferent axons. In: Gildenberg P.L. (Ed). The Initial Processing of Pain and its Descending Control Spinal and Trigeminal Systems (1992), Basel, Karger 87-108
18. Martínez R.V., Reval M., Campos M.D., Terrón J.A., Domínguez R., and López-Muñoz F.J. Involvement of peripheral cyclooxygenase-1 and cyclooxygenase-2 in inflammatory pain. J. Pharm. Pharmacol. 54 (2002) 405-412
19. Mehta V., Johnston A., Cheung R., Bello A., and Langford R.M. Intravenous parecoxib rapidly leads to COX-2 inhibitory concentration of valdecoxib in the central nervous system. Clin. Pharmacol. Ther. 83 (2008) 430-435
20. Netter P., Lapicque F., Bannwarth B., Tamisier J.N., Thomas P., and Royer R.J. Diffusion of intramuscular ketoprofen into the cerebrospinal fluid. Eur. J. Clin. Pharmacol. 29 (1985) 319-321
21. Pham-Marcou T.A., Beloeil H., Sun X., Gentili M., Yaici D., Benoit G., Benhamou D., and Mazoit J.X. Antinociceptive effect of resveratrol in carrageenan-evoked hyperalgesia in rats: prolonged effect related to COX-2 expression impairment. Pain 140 (2008) 274-283
22. Popp L., Häussler A., Olliges A., Nüsing R., Narumiya S., and Geisslinger G. Comparison of nociceptive behavior in prostaglandin E, F, D, prostacyclin and thromboxane receptor knockout mice. Eur. J. Pain. (2008) 10.1016/j.ejpain.2008.09.001 (Epub ahead of print)
23. Rouzer C.A., and Marnett L.J. Structural and functional differences between cyclooxygenases: fatty acid oxygenases with a critical role in cell signaling. Biochem. Biophys. Res. Commun. 338 (2005) 34-44
24. Samad T.A., Moore K.A., Sapirstein A., Billet S.A., llchorne A., Poole S., Bonventre J.V., and Woolf C.J. Interleukin-1beta-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature 410 (2001) 471-475
25. Schuh-Hofer S., Tayefeh M., Reuter U., Dirnagl U., and Arnold G. Effects of parecoxib on plasma protein extravasation and c-Fos expression in the rat. Headache 46 (2006) 276-285
26. Sekiguchi M., and Shirasaka M. Potent anti-inflammatory/analgesic effects of lornoxicam in comparison to other NSAIDs: a c-fos study in the rat. Inflammopharmacology 5 (1997) 331-341
27. Smith C.J., Zhang Y., Koboldt C.M., Muhammad J., Zweifel B.S., Shaffer A., Talley J.J., Masferrer J.L., Seibert K., and Isakson P.C. Pharmacological analysis of cyclooxygenase-1 in inflammation. PNAS 95 (1998) 13313-13318
28. Soberman R.J., and Christmas P. The organization and consequences of eicosanoid signaling. J. Clin. Invest. 111 (2003) 1107-1113
29. Svensson C.I., and Yaksh T.L. The spinal phospholipase-cyclooxygenase-prostanoid cascade in nociceptive processing. Annu. Rev. Pharmacol. Toxicol. 42 (2002) 553-583
30. Takemiya T., Matsumura K., and Yamagata K. Roles of prostaglandin synthesis in excitotoxic brain diseases. Neurochem. Int. 51 (2007) 112-120
31. Talley J.J., Bertenshaw S.R., Brown D.L., Carter J.S., Graneto M.J., Kellogg M.S., Koboldt C.M., Yuan J., Zhang Y.Y., and Seibert K. N-[[(5-methyl-3-phenylisoxazol-4-yl)-phenyl]sulfonyl]propanamide, sodium salt, parecoxib sodium: a potent and selective inhibitor of COX-2 for parenteral administration. J. Med. Chem. 43 (2000) 1661-1663
32. Tegeder I., Niederberger E., Vetter G., Bräutigamm L., and Geisslinger G. Effects of selective COX-1 and -2 inhibition on formalin-evoked nociceptive behaviour and prostaglandin E(2) release in the spinal cord. J. Neurochem. 79 (2001) 777-786
33. Uzan A. The unexpected side effects of new nonsteroidal anti-inflammatory drugs. Expert Opin. Emerg. Drugs 10 (2005) 687-688
34. Vane J.R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. New. Biol. 231 (1971) 232-235
35. Warner T.D., and Mitchell J.A. Cyclooxygenase-3 (COX-3): filling in the gaps toward a COX continuum?. PNAS (USA) 99 (2002) 13371-13373
36. Wei F., Dubner R., and Ren K. Laminar-selective noradrenergic and serotoninergic modulation includes spinoparabrachial cells after inflammation. Neuroreport 10 (1999) 1757-1761
37. Wei F., Dubner R., and Ren K. Nucleus reticularis gigantocellularis and nucleus raphe magnus in the brain stem exert opposite effects on behavioral hyperalgesia and spinal Fos protein expression after peripheral inflammation. Pain 80 (1999) 127-141
38. Yaksh T.L., Dirig D.M., Conwaym C.M., Svensson C., Luo Z.D., and Isakson P.C. The acute antihyperalgesic action of nonsteroidal, anti-inflammatory drugs and release of spinal prostaglandin E2 is mediated by the inhibition of constitutive spinal cyclooxygenase-2 (COX-2) but not COX-1. J. Neurosci. 21 (2001) 5847-5853